Arno Andrew 4

What Happened

• Arno Andrew, a director of Insight Molecular Diagnostics, was granted 32,331 restricted stock units (RSUs) on June 11, 2026. The award was granted at $0.00 per share (no cash paid at grant), total reported value $0 on the Form 4. The RSUs will convert into shares if and when they vest.

Key Details

• Transaction date: June 11, 2026; Filing date (Form 4): June 15, 2026. Grant price reported: $0.00 per RSU.
• Shares acquired: 32,331 RSUs reported as newly granted.
• Shares owned after transaction: not specified in the filing for the RSUs; filing notes the Reporting Person has voting/disposal rights over shares held by JBA Investments LLC and MJA Investments LLC (see footnotes).
• Footnotes of note:
  • F1: RSUs vest on the date of the next annual meeting of shareholders, subject to continued service from grant to vesting date.
  • F2/F3: The reporting person is manager of JBA Investments LLC and MJA Investments LLC and has voting/disposal rights over shares those entities hold.
• No indication in this filing of a sale, option exercise, 10b5-1 plan, or tax-withholding share surrender.

Context

• RSUs are a form of equity compensation: no cash changes hands at grant; they convert to shares only upon vesting. Director awards are common as part of board compensation and do not by themselves signal a buy or sell decision.
• For retail investors, purchases can be a stronger signal of insider conviction than awards. This filing documents a compensation grant rather than a personal purchase or sale.